As 2018 witnessed unexpected mergers and partnerships, robust digital health innovations and continued policy shifts in the healthcare sector, at Elsevier, we think 2019 will bring about significant changes in health IT infrastructure with patient data at the center of it all.
Given that the #1 funding category in 2018 is data analytics, we anticipate that 2019 will usher in a variety of advanced analytics demonstrations. Many will be novel in the output generated but the uncertainty of real-world clinical value will continue. So, a demonstration of the computational capabilities will be most significant, since that opens the door to a range of possibilities. Additionally, there will be a shift in emphasis on “big data” to “small data” analytics as healthcare systems focus to leverage existing data to improve clinical and operational processes.
The most substantial real-world AI applications will be in image processing through early stage machine learning for areas like radiology and dermatological lesions. Secondary spin-offs could be self-monitoring / telemedicine apps for dermatology and tele-radiology.
Hospital EHR deployments outside the US will increasingly follow in its footsteps by including evidence-based clinician decision support tools linked to CPOE (computerized physician order entry) and care management.
IDNs or integrated delivery networks will increasingly implement pathways, including treatment selection and care coordination, to reduce unwarranted variation of care.
Boundaries between patient-led, home-based self-care and physician-led outpatient care increasingly blur, so these personal health logs will merge with primary care decision support tools in new and uniquely challenging ways.
Through data liquidity and third-party app integration with EHRs, there will be a refinement of clinical evidence based on clinical data captured through care delivery.
Patients as consumers will take control of and store their personal health and clinical data in applications of their choice in the cloud. Since May, GDPR requires data controllers to turn over data to consumers and patients on demand and in usable electronic formats. Apple has made notable inroads with HealthKit, and Microsoft has revived Health Vault. Even in privacy conservative Germany, a large group of insurers, hospital chains and industry partners are finally cooperating (e.g. Vivy). For patients in Denmark and Estonia, this has already been in play with online access to health records through the national health systems.
This is an older prediction expected by many to be imminent. After years of exponential decline, the cost of high-quality whole genome sequencing has stalled. There are barriers to broad adoption and economies of scale because many consumers still have privacy concerns and are hesitant to disclose "pre-existing conditions". On the other hand, clinicians don’t have the tools to interpret complex results (this is an issue, considering that an estimated 10% of the human population has some form of a rare disease).
There will be an increase in next generation sequencing (NGS) and more AI applications will take place in genomics related to oncology, with refined genetic variants and subtypes leading to more precision medicine in treatment options.
Patient data from routine clinical practice (EHRs, radiology images, genomics) and personal health devices will increasingly drive medical research. Precision medicine requires ever larger data sets and increasingly specific genomes (e.g. in the case of breast cancers). The difficulty lies in hospitals being reticent about sharing this data, since patient privacy is paramount.
However, the solution could be found in IoT technology; allowing sophisticated distributed analytics on site so that the data never leaves the virtual walls of the hospital. Microsoft Azure, Kubernetes, and Open Stack are the most likely candidates for this, with AWS staking a claim as well.